ASTRO 2025 Prostate Cancer

Viewing 1-20 of 82 articles

ASTRO 2025: Hallmark Interferon-Alpha Response Analysis in Localized Prostate Cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, 9902, 0126, and 0521 Clinical Trials

ASTRO 2025: Genomic Classifier and Multimodal AI Biomarker in Localized Prostate Cancer: Two Sides of the Same Coin

ASTRO 2025: Discussant: Biomarker Breakthroughs in Prostate Cancer

ASTRO 2025: Predictive Role of Tumor Fraction and Copy Number Alteration Burden in mCRPC Patients Receiving Tandem Actinium-Lutetium Radionuclide Therapy

ASTRO 2025: Influence of HSD3B1 Genotype on Prostate Cancer Outcomes Following Definitive Radiation Therapy with ADT: A Retrospective Analysis of the Million Veterans Program

ASTRO 2025: Validation of Six Androgen Production, Uptake and Conversion Genes in the ECOG-ACRIN E3805 CHAARTED Prostate Cancer Trial

ASTRO 2025: Testosterone Recovery post ADT in Intermediate Risk Prostate Cancer Patients: Does a Higher Dose of Radiotherapy Impact on Survival? Long-Term Data from a Phase III Trial

ASTRO 2025: Post-Treatment ctDNA Alterations as Predictors of Response to 177Lu-PSMA-617 in mCRPC

ASTRO 2025: Validation of a Prognostic Multimodal Artificial Intelligence Model in Asian Prostate Cancer Patients from Singapore

ASTRO 2025: Evaluating Molecular Response Using 68Ga-PSMA-PET/CT in Prostate Cancer Patients with Pelvic Lymph Node Metastasis Undergoing Definitive Radiotherapy: Clinical Significance and Implications

ASTRO 2025: Prognostic Value of Quantitative Imaging Metrics Obtained in Routine Clinical Practice in a Cohort of Patients Treated with PSMA-RLT

ASTRO 2025: Germline Indicators of Radiation Therapy Response in Both Aggressive and Non-Aggressive Prostate Cancer Subtypes

ASTRO 2025: Discordance of Adverse Molecular Features between the 22-Gene Genomic Classifier Score, Histologic Grade, and NCCN Risk Groups: Analysis of Over 200,000 Patients

ASTRO 2025: Prospective Phase II Trial of Short Course Androgen Deprivation, Pelvic SBRT, and Brachytherapy Boost for NCCN High-Risk Prostate Cancer with Low-Intermediate Risk Decipher Genomic Score

ASTRO 2025: Identifying Optimal Candidates for PSMA PET Staging of Newly Diagnosed Intermediate Risk Prostate Cancer: A Report from the National Veterans Affairs System

ASTRO 2025: A Phase I/Ib, Single Arm Study of Two Fraction SBRT with Simultaneous Integrated Boost for the Treatment of Localized Prostate Cancer: Early Toxicity Outcomes

ASTRO 2025: Treatment Outcomes and Prognostic Factors of Carbon Ion Radiation Therapy for Localized Prostate Cancer: A Single-Institution Retrospective Study of over 7000 Patients

ASTRO 2025: PURE-MRI: An International Study Assessing Physician Accuracy in Delineating the Prostate and Urethra on Prostate MRI

ASTRO 2025: A Dynamic Treatment Strategy for Oligometastatic CSPC: Integrating Molecular Imaging and SBRT to Personalize Systemic Therapy Intensification and De-Intensification

ASTRO 2025: Implications on Radiation Treatment Planning of 18F-Fluciclovine PET/CT in Patients with Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET/CT

1
2
3
4
5